● "We are very pleased to reach an important strategic cooperation with Yarrow regarding the innovative humanized Thyroid-Stimulating Hormone Receptor (TSHR) antagonistic monoclonal antibody, GenSci098." Regarding this collaboration,Dr. Lei Jin, General Manager of Changchun High-Tech Group, Founder and General Manager of GenSci, Chief ScientistCurrently, the company is transitioning from a single growth hormone business to a new stage where "three main businesses" (growth hormone, innovative drugs, and R&D BD revenue) drive together, fostering a coexistence of diversified businesses. This is GenSci's first externally licensed pipeline, marking a substantive realization phase of the company's strategic transformation and demonstrating the potential of GenSci’s global development strategy. "The indications covered by this agreement—thyroid eye disease and Graves' disease (also known as diffuse toxic goiter)—have a vast market space, with North America and the Asia-Pacific region combined accounting for over 65% of the global market share. We have granted the global development and commercialization rights of GenSci098 assets outside of Greater China to our North American partner. Both parties will leverage their respective strengths to create synergies, align with the highest international R&D standards, jointly accelerate the global development of this pipeline, fully explore its commercial potential, and aim to provide new treatment options to patients worldwide as soon as possible."
● Dr. Rebecca Frey, President and CEO of Yarrow Bioscience"We are delighted to collaborate with GenSci in the global development of GenSci098 for Graves' disease and thyroid eye disease. This drug has a clear target and a novel mechanism of action, offering the potential for a new treatment option for patients. We look forward to working closely with the GenSci team to bring this promising therapy to market as soon as possible."
● RTW Partner and President Peter FongHe added, "The collaboration with GenSci continues our commitment to advancing scientific translation through deep cooperation. The Yarrow team possesses excellent scientific and execution capabilities, and we believe that by combining GenSci’s R&D strength, we can fully unlock the clinical value of GenSci098, benefiting patients worldwide."
GenSci098 is a Class 1 novel biologic therapeutic drug independently developed by GenSci. It is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR). The drug specifically binds to TSHR in the thyroid or extrathyroidal tissues (such as retro-orbital tissue), blocking the binding of thyroid-stimulating hormone or pathogenic stimulating antibodies to the receptor and downstream signal transduction, thereby inhibiting the excessive synthesis and release of thyroid hormones, alleviating inflammation and proliferation of retro-orbital tissue, and reducing hyaluronic acid secretion.Effectively Control Hyperthyroidism and Related Complications。
GenSci098 addresses hyperthyroidism issues from the pathogenesis, preventing recurrence or progression of the disease.，May allow patients with recurrent, poorly controlled moderate to severe Graves' disease to avoid surgery or radioactive iodine.Treatment, simultaneous treatment and prevention of Graves' disease-related complications such as thyroid eye disease, etc., brings innovative causal therapies to patients with Graves' disease, offering the possibility of a cure. Additionally, GenSci098 may potentially reduce or avoid the toxic side effects of antithyroid drugs in the future, with its subcutaneous injection method.It also brings convenience to patients, and can be called "Best-in-class".
The global market for thyroid disease treatment has vast potential. According to an industry report by Market Research Future (MRFR), a well-known global market research firm, the global market size for thyroid eye disease treatment is projected to reach approximately USD 2.67 billion by 2025 and is expected to grow to USD 5.45 billion by 2033, with an annual compound growth rate of about 9.34%. Meanwhile, the market for the treatment of another indication, Graves' disease, is anticipated to increase from USD 3.759 billion in 2025 to USD 6.037 billion by 2035, demonstrating steady demand growth potential. GenSci098’s strategic positioning in these two major indications is set to compete in a future market worth billions of dollars, showing promising prospects.
Currently, the clinical trial of this drug for thyroid eye disease was approved for conduct in both China and the U.S. as early as August 2024; its clinical trial application for the treatment of Graves' disease (also known as diffuse toxic goiter) was also approved by the National Medical Products Administration in October 2025.
GenSci takes research and development (R&D) innovation as its core strategy, with R&D investment showing positive growth for 12 consecutive years. In 2024, R&D expenses accounted for 22% of sales revenue (top 10 among A-share pharmaceutical companies). Firm, continuous, and high R&D investment has provided solid support for the advancement of its pipeline. The company currently holds a pipeline covering multiple fields such as endocrine metabolism, immunology and respiratory, oncology, and women's health. Several innovative pipelines in clinical stages demonstrate "best-in-class or first-in-class" potential. The company adheres to the principle of "tailoring BD strategies for each innovative drug molecule based on clinical competitive potential," aiming to maximize pipeline value.
This collaboration represents a key practice and substantive outcome for GenSci, aiming to integrate independent research and development with external licensing or co-development strategies, while actively consolidating international resources. By complementing strengths with international professional teams, GenSci is taking a more active role in global drug innovation, promoting the benefits of R&D achievements originating from China to reach a broader patient population.
